Table 2.

Treatment regimens in patients with multiple myeloma at the time of COVID-19 diagnosis

	Number
All patients	100
Patients with ongoing treatment	86
Bortezomib-including regimen	20
Carfilzomib-including regimen	15
Daratumumab-including regimen	24
Ixazomib-including regimen	6
Lenalidomide maintenance	22
Other treatmentsa	10
Prior MEL/ASCT	39
Prior allogeneic transplant	2
Not on treatment	12
Missing information regarding treatment status	2

^aOther treatments included DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin), low-dose melphalan, panabinostat, iberomid, chlarithromycin, venetoclax, selinexor, and AMG-701.

Abbreviation: MEL/ASCT, melphalan/autologous stem cell transplant.